Ocata Therapeutics Inc fka OCAT

[rocky301]

10K filing,

A few quick Notables:

http://www.sec.gov/Archives/edgar/data/1140098/000114420410013897/v177442_10k.htm

The number of outstanding shares of the registrant’s Common Stock, $0.01 par value, was 747,932,679 shares as of March 12, 2010.

As of March 16, 2010, we had 14 full-time employees,

On January 29, 2010, the Company signed a new lease to move from its Worcester facility to a new 10,607 square-foot facility in Marlboro, Massachusetts. The lease term is from April 1, 2010 through June 30, 2015. Monthly base rent in 2010 will be $12,596.

On March 10, 2010, the Company issued 5,000,000 shares of its restricted common stock to each of its directors in connection with their services on the board of directors.

On March 2, 2010, the Company delivered its first tranche notice to Optimus Life Sciences Capital Partners, LLC under the Series B redeemable preferred stock (see Note 11) for funding in the amount of $1,500,000. On March 8, 2010, in connection with the funding, the Company issued 19,285,714 shares of its common stock upon exercise of the same number of warrants, which were granted simultaneously with the Company’s tranche notice. The Company received a secured promissory note in the amount of $2,025,000 to settle the warrant exercise. Under the terms of the agreement, the Investor is required to provide funding on the preferred stock facility on or within 10 trading days from the Company’s tranche notice date.

We are not in full compliance with some of our license agreements. We are not in full compliance with some of our licenses (see Our Intellectual Property in the BUSINESS section of this 10k) and due to limited financial resources we cannot guarantee that we will regain full compliance status. If we are unable to be in compliance with our license agreements, our business may be harmed.

As of December 31, 2009, on an aggregated basis our debt and preferred stock financings may result in being converted into 148,000,000 shares of our common stock, and warrants and options that may be converted into approximately 219,000,000 shares of our common stock.

Gary D. Aronson v. Advanced Cell Technology, Inc., Superior Court of California, County of Alameda, Case No. RG07348990. John S. Gorton v. Advanced Cell Technology, Inc, Superior Court of California, County of Alameda Case No. RG07350437.
A trial date has been set for March 22, 2010.


HOLDERS
As of March 12, 2010, there were approximately 214 shareholders of record of our common stock.

Beneficial Ownership of Directors, Officers and 5% Stockholders
Directors and Executive Officers as a Group ( 5 Persons) 39,863,715 5.19 %